Physician profile
Robert Edward Lee
NPI 1003866542
$4,153.93
in general payments reported to CMS, 2019-2025
24 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $338 · 2021: $576 · 2022: $585 · 2023: $532 · 2024: $831 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056 · Travel and Lodging: $39.20 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.34 |
| Travel and Lodging | $39.20 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.73 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $557.30 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $529.71 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Sun Pharmaceutical Industries INC. | $482.30 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $312.75 | 2019-2021 | |
| Allergan, INC. | $312.06 | 2019-2022 | |
| Oyster Point Pharma, INC. | $262.46 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $184.44 | 2021-2022 | |
| Dompe US, INC. | $125.29 | 2022-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $95.35 | 2020-2021 | |
| New World Medical,INC. | $81.97 | 2022-2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Tarsus Pharmaceuticals, INC. | $75.38 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $66.95 | 2019-2023 | |
| Aerie Pharmaceuticals, INC. | $66.36 | 2019-2021 | |
| Ocular Therapeutix, INC. | $59.91 | 2019-2025 | Dextenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $59.61 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $42.93 | 2021-2022 | |
| Ivantis, INC | $40.09 | 2019-2021 | |
| Eyepoint US, INC. | $32.42 | 2019 | |
| Rayner Intraocular Lenses Limited | $27.02 | 2022 | |
| Rxsight INC | $22.60 | 2022 | |
| Amgen INC. | $18.05 | 2025 | Tepezza |
| Omeros Corporation | $13.16 | 2019 | |
| Harrow Eye, LLC | $13.09 | 2023 | Ilevro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.